Sydney's major cancer centres manage substantial prostate cancer patient populations requiring Abiraterone therapy for mCRPC. Abiranamo offers Australian patients this treatment at significantly reduced cost compared to private market pricing.
While the PBS subsidises Zytiga for eligible patients, those outside eligibility criteria or facing private costs can access generic Abiranamo at a fraction of the price.
|
FAQ: What PBS eligibility criteria typically apply to
prostate cancer treatments like Zytiga in Australia? PBS subsidy for
Abiraterone-based treatments generally requires specific staging criteria
(such as confirmed metastatic disease) and often prior treatment history
requirements. Eligibility criteria can change periodically, so patients
should check current PBS listings with their oncologist. Those not meeting
criteria face the full private cost, where generic alternatives provide
meaningful savings. |
